Delivery Order SPE2DB22D2006-SPE2DB26FV5XB
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp valued at $46,395.18 for the supply of RINVOQ ER 15 mg tablets (30-count units) under a firm fixed price contract. This non-competitive delivery order, issued on November 13, 2025, with an ultimate completion date of November 14, 2025, will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a child contract action under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $17,605.35 on August 20, 2025, for the supply of RINVOQ ER 30 mg tablets (30-count units). This is a firm fixed-price, competitively awarded contract with no set-aside designation and an ultimate completion date of August 21, 2025. The place of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. This delivery order is a child contract...
- The Defense Logistics Agency awarded a $32,318.92 firm fixed price delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) on August 1, 2025, with an ultimate completion date of August 4, 2025. This non-competitive delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The product will be performed at...
- The Defense Logistics Agency awarded a $30,275.00 firm fixed-price delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) on August 15, 2025, with an ultimate completion date of August 18, 2025. This non-set-aside competitive award represents a child delivery order under AmerisourceBergen's substantial Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The order will be performed...
- The Defense Logistics Agency awarded a delivery order valued at approximately $40.2K to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) on September 3, 2025, with completion scheduled for September 4, 2025. This firm fixed-price delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (valued at $1 billion through December 2026), which serves as a comprehensive pharmaceutical supply vehicle...
- The Defense Logistics Agency awarded a $197,052.56 firm fixed-price delivery order to AmerisourceBergen Drug Corp on September 17, 2025, for RINVOQ ER 15 mg tablets (30-count units). This is a non-set-aside competitive award with an ultimate completion date of September 18, 2025, to be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical,...
- The Defense Logistics Agency awarded a $80,832.18 delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 45 mg tablets (28-count units) on July 22, 2025, with completion scheduled for July 23, 2025. This firm fixed-price, competitively awarded contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The contract involves no set-aside...
- The Defense Logistics Agency awarded a delivery order valued at $22,851.98 to AmerisourceBergen Drug Corp for RINVOQ ER 30 mg tablets (30-count unit dose packages) on July 18, 2025, with a completion date of July 21, 2025. This firm fixed-price, competitively awarded contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The contract involves no set-aside...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on November 3, 2025, for RINVOQ ER 15 mg tablets (quantity 30) with a ceiling value of $96,729.24. This firm fixed price delivery order, set to be completed by November 4, 2025, is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical designated SPE2DX, valued at $999,999,999.00 through December 2026. The award is non-competitive and represents a continuation...
- The Defense Logistics Agency awarded a delivery order valued at $13,485.90 to AmerisourceBergen Drug Corp for RINVOQ ER 15 MG tablets (30-count units) on October 20, 2025, with completion targeted for October 21, 2025. This competitive award, issued under a firm fixed-price delivery order contract with no set-aside designation, represents a pharmaceutical supply delivery to be performed at AmerisourceBergen's Conshohocken, Pennsylvania location. The order is a child action under...
- SPE2DB22D2006Indefinite Delivery Contract
- SPE2DB22D2006-SPE2DB26FV5XBDelivery Order
The Defense Logistics Agency awarded a delivery order valued at approximately $25,052 to AmerisourceBergen Drug Corp for the supply of RINVOQ ER 15 mg tablets (30-count units). This firm fixed-price, competitively awarded contract was executed on October 28, 2025, with an ultimate completion date of October 29, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated as SPE2DX and valued at $999,999,999.00 through December 2026. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, serves as a critical vendor for federal medical procurement, particularly for military and veteran healthcare systems. As a prime contractor on the SPE2DX global pharmaceutical support vehicle, the company supplies a comprehensive range of pharmaceutical products across multiple therapeutic domains to support military healthcare programs worldwide. This delivery order for RINVOQ ER, a prescription medication used in treating certain autoimmune conditions, exemplifies the company's role in fulfilling specialized pharmaceutical requirements for the Defense Health Agency and other federal healthcare entities through the flexible IDC framework.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $25.1k | 10/28/25 |